

About Unitaid

8 December 2017

Sanne Fournier-Wendes, Senior Advisor to the ED




Agenda

- 1 Unitaid overview
- 2 Our portfolio
- 3 Collaboration with GHIT Fund

Unitaid overview

Growth in development assistance

Development assistance for health (\$B)



Source: IHME (Institute for Health Metrics and Evaluation)

Unitaid's mission relies on 3 strategic objectives



**Maximize the effectiveness of the global health response
by catalyzing equitable access to better health products**

Innovation

*Linking pipelines to
frontlines*


Access

*Overcoming
market barriers*


Scalability

*Creating conditions for
scale-up*


Unitaid plays a role at 3 critical moments



Unitaid connects the upstream to the downstream



Unitaid's Operating Model



Partner engagement is key through entire process




Anticipate and respond to country needs

Anticipate upstream innovation


Ensure readiness to scale-up including funding

Our portfolio


Unitaid's Core Investment Areas



Unitaid's Portfolio as at Oct 2017



40 grants



US\$ 1 bio.

TB: New paediatric formulation

Children have been under-treated for decades

Unitaid has introduced first child-friendly TB medicine


- ~10% of all TB cases occur among children
- At least 1 million children become ill with TB each year
- TB medicines have been around since 1950s – but no child-friendly version

- 2010: Revised WHO recommendation for TB treatment in children but no manufacturers were responding
- Unitaid & its partners (TB Alliance) have brought child-friendly fixed dose combination to market

Today procured in
more than
70 countries

Malaria: Injectable Artesunate - a dramatic reduction in child mortality

Number of vials procured (m)



66k children's lives
saved / year




ROI > 100

Collaboration with GHIT Fund

Engagement between GHIT & Unitaid and areas of continued collaboration

- Common **vision & interests**: bring access to new health technologies (e.g. drugs, diagnostics) with potential for game changing impact in developing world
- Participation in **GHIT annual partner meeting** in 2016 and in **R&D Forum** in December 2017
- **Bi-lateral discussions**: 3 meetings in London, New York UNGA 2017 and Geneva Oct 2017
- Mapping in process of potential GHIT investments that could be transitioned to Unitaid, e.g.
 - Common **partners / stakeholders** (Gates Foundation, Otsuka, TB Alliance)
 - Common **priority countries** (e.g. Uganda, Tanzania, Burkina Faso)
 - Common **priority areas** (e.g. Malaria in children, Tuberculosis)

Area of value chain suited to collaboration with GHIT



Any questions? Thank you